Specimen Management in the Lab: What’s Actually Going Wrong & How to Fix It

If you’ve spent any meaningful time in a research lab, you know that specimen management sounds straightforward until it isn’t. Collect samples, label them, store them, track what happens to them. In theory, simple. In practice, it’s one of the most persistent sources of wasted time, lost data, and quiet frustration in labs of every size. The freezer inventory that exists only in someone’s head. The Excel sheet that three people edit independently. The unlabeled tube that could be anything from a bacterial lysate to a patient-derived serum sample. These aren’t edge cases. They’re Tuesday.

What does lab specimen management actually involve?

Specimen management covers the full lifecycle of any physical sample your lab works with: biological materials like bacterial cultures, cell lines, tissue sections, blood, serum, DNA and RNA extracts; chemical and biochemical specimens such as reagent libraries, metabolite panels, and antibody stocks; clinical specimens including biopsies, saliva, urine, and plasma; environmental samples; and genomic or proteomic materials such as sequencing libraries, CRISPR reagents, and protein preparations.

Each of these has its own handling requirements, stability windows, regulatory considerations, and downstream dependencies. A microbial culture collection has different storage and passage-tracking needs than a biobank of clinical serum samples. A reagent library supporting a drug screening campaign needs different metadata than soil samples in an ecology study.

The common thread is that every specimen needs to be unambiguously identified, traceable through every interaction, stored under the right conditions, and documented well enough that someone else - or you, six months from now - can pick up exactly where things left off.

Where lab specimen management breaks down

Rather than listing generic problems like “manual errors” and “inefficiencies,” it’s more useful to describe the specific failure modes that are hard to catch in the moment and expensive to fix after the fact.

Inconsistent labeling

When two lab members change a labeling convention and no one’s around to document the transition, the metadata suffers even if the samples are fine. Or, for example, if there are no enforced standards, no guaranteed links to experimental contexts, or no redundancy if the label degrades. With most labs identifying specimens based on handwritten labels or locally printed stickers, the information on it is simply whatever the person collecting the sample decided was important at that moment. A freezer box of DNA extracts can become effectively useless because of these “slip ups.”

Tracking fragments across disconnected systems

When someone asks, “How many aliquots of strain X do we have, and which experiments have used them?”, answering probably requires cross-referencing three systems, interpreting two people’s handwriting, and probably opening a freezer to physically count. This is what you get when specimens live in a freezer log, or experimental use gets recorded in a notebook or ELN, or inventory levels get tracked somewhere else entirely. (Or not at all.)

In a lab of 15 people, this is annoying. In a lab of 80, it’s a structural problem that costs hours every week.

Chain of custody gaps that surface at the worst possible time

If your lab operates under any regulatory framework - GLP, GCP, ISO 17025, or institutional biosafety protocols - you need to demonstrate who handled a specimen, when, and what they did with it. In manual systems, this documentation is reconstructed after the fact, if it’s created at all. The gap is invisible until an auditor asks for it, or until a result is challenged, and you can’t demonstrate the integrity of the sample it was based on.

For biotech and pharma labs moving toward IND-enabling studies, this isn’t a nice-to-have. It’s a gating requirement.

Specimens degrade silently

A freezer that drifts two degrees overnight. A reagent past its validated stability window. A cell line aliquot that’s been through one too many freeze-thaw cycles because people keep pulling from the same stock instead of working from designated working aliquots. None of these announce themselves. You discover them when an assay fails, when results don’t replicate, or when a QC check catches something downstream. By then, you’ve lost not just the specimen but potentially weeks of work that depended on it.

Scaling makes every weakness structural

A five-person academic group can often manage specimens through informal systems and institutional knowledge; but when that group grows to 20, or when a biotech scales from 30 to 100 people, every informal practice becomes a liability. New team members don’t know the unwritten conventions. Storage space gets allocated ad hoc. Nobody owns the inventory as a whole. The transition from “we manage” to “we’ve lost control” happens gradually and usually isn’t recognized until something forces the issue.

What a centralized specimen management system looks like

The failure modes above share a root cause: fragmentation. Fragmented identification, fragmented tracking, and fragmented documentation. Addressing them means going beyond adding more tools. Rather, when you replace the patchwork with a single system where specimen data, experimental records, and inventory all live together:

Specimens become findable in seconds, not minutes

When your storage infrastructure is modeled digitally - down to the freezer, shelf, rack, box, and position - retrieving a specimen means searching, locating, and closing the freezer. Not holding the door open while scanning labels, which incidentally is one of the most common causes of the temperature excursions mentioned earlier. These time savings compound across every person in the lab, every day. This search also tells you about the sample's current state, including whether it's in use, reserved, depleted, or awaiting QC (quality control), so you don't make the trip to the freezer just to find out someone took the last vial yesterday.

Traceability becomes automatic, not administrative

When every interaction with a specimen - creation, transfer, aliquoting, use, disposal - is logged as a natural consequence of working in the system, chain of custody stops being something your team must remember to document. For academic labs, this supports reproducibility and publication integrity. For regulated environments, it generates the audit trail that GLP, GCP, and ISO frameworks require without adding bureaucratic overhead.

Sample lineage stays intact across months and team members

Structured and queryable relationships between samples mean you can trace any result back to its source. This is particularly relevant in molecular biology and microbiology workflows, where a single source specimen can generate dozens of derivatives over months of work. For example, parent-child relationships between the original clinical sample and its aliquots, the master cell bank and its passages, the genomic extraction, and the sequencing library. When you can't explain how these are related, you have an accumulation of tubes instead of a managed collection.

Problems get caught before they cascade

Continuous environmental monitoring with automated alerts means a freezer excursion triggers a notification - not a failed assay three weeks later. Expiry tracking means your team acts on specimens approaching their stability window rather than discovering degradation downstream. The shift from reactive to proactive is where most of the hidden cost savings live.

Growth doesn’t break your processes

A system that handles 500 specimens with the same rigor as 50,000 means you don’t rebuild your infrastructure every time the lab scales. Batch operations handle high-throughput intake without sacrificing individual-level traceability. Role-based access ensures that as your team grows, accountability and data security grow with it. This matters particularly during the transitions that growing biotechs know well - the Series A hire surge, the CRO partnership, the multi-site expansion.

Collaboration happens without losing control

Sharing specimen data with a CRO, an academic collaborator, or a second site shouldn’t require exporting spreadsheets and hoping version control holds. Secure transfer of relevant data - without exposing your entire inventory - is what makes multi-party research manageable.

At SciSure, these capabilities come together in a single platform that integrates ELN and LIMS - meaning specimen data isn’t separated from the experimental records that give it context. It also means security stops being patchworked. Encryption, access controls, hosting compliance, and audit logging are properties of the system, not properties assembled across five different vendors with five different review processes.

This architectural choice reflects a conviction that specimen management doesn’t exist in isolation: it’s part of how research gets done, and the tools should reflect that.

How Arctic Therapeutics consolidated their lab workflows

After adopting SciSure, Arctic Therapeutics - a growth-stage Icelandic biotech running drug development programs across Alzheimer's, Parkinson's, and rare-disease research - now works with consolidated samples, inventory, equipment, and experiments into a single system. The team reports having saved approximately 2 hours per week on registration and inventory tasks alone, with full sample-and-reagent traceability and audit-ready documentation through controlled access, electronic signing, and record locking.

Before centralizing, the laboratory team of around 10 specialists managed experiment documentation, inventory, and equipment logs across spreadsheets, paper records, and a mix of digital platforms. Samples and reagents weren't QR coded, so traceability was limited - a real problem for a lab operating under ISO 15189 (the international standard for quality and competence in medical laboratories) and supporting clinical workflows.

As Laboratory Director Olga Ýr Björgvinsdóttir summarizes, the team can now "save at least 2 hours per week, while also strengthening our ISO 15189 compliance."

How to improve specimen management in your lab

• Start with centralization, not optimization.  
  The most damaging decision a growing lab makes is layering another tool on top of existing fragmented processes. If your specimens, inventory, and experimental records live in three different places, bringing them together will deliver more value than improving any one of them individually.

• Define your metadata schema before you start entering data.  
  Decide what fields every specimen type needs and enforce them. The time spent upfront saves an order of magnitude more in retrieval, reporting, and troubleshooting later.

• Automate identification.  
  Barcode labeling eliminates the single largest source of specimen management errors. The cost is trivial compared to a single misidentified sample in a regulatory submission or a published study.

• Invest in training as an ongoing practice.  
  A system is only as good as the consistency with which people use it. This is especially important in academic labs with regular student and postdoc turnover, and in growing companies onboarding new scientists rapidly.

• Monitor storage conditions continuously, not reactively.  
  If you’re only checking freezer temperatures when something seems wrong, you’re accepting risks you don’t need to.

The work isn't glamorous, but it matters.

Nobody gets into science because they’re passionate about freezer inventory, but it is foundational. The integrity of your data depends on the integrity of your samples. The efficiency of your lab depends on how quickly people can find, verify, and use what they need. And your ability to meet regulatory requirements, reproduce results, and collaborate across teams depends on having a system that doesn’t rely on individual memory or informal conventions.

Whether you’re a small academic group trying to stay organized or a growing biotech preparing for your first regulatory submission, the principles are the same. The only question is whether you systematize them now or pay the cost of not doing so later.

If this resonates, we’d welcome a conversation - not a sales pitch, but a practical discussion about what’s working in your lab and what isn’t.